Experts discuss the importance of initiating blinatumomab treatment for acute lymphoid leukemia in academic centers for ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate ...

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration.

Researchers at Weill Cornell Medicine and the University of Adelaide have developed GoT-Multi, a tool that tracks multiple ...

A novel tool created by researchers at Weill Cornell Medicine and the University of Adelaide has improved the capacity to ...

University of Cambridge scientists have used human stem cells to create three-dimensional embryo-like structures that ...

CERo Therapeutics (CERO) announces it has concluded the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid ...

Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial ...

The results highlight an in vivo patient-derived xenograft (PDX) model of relapsed/refractory T-PLL that reproduced key human clinicopathological features of the disease. In this model, SLS009 ...

Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemia ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation ...